Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients - Shapiro, Amy D.; Ragni, Margaret V.; Valentino, Leonard A.; Key, Nigel S.; Josephson, Neil C.; Powell, Jerry S.; Cheng, Gregory; Thompson, Arthur R.; Goyal, Jaya; Tubridy, Karen L.; Peters, Robert T.; Dumont, Jennifer A.; et al. (Blood, 2012)
Keywords: Adolescent; Adult; Aged; Biological and medical sciences; Clinical Trials and Observations; Factor IX - metabolism; Female; Half-Life; Hematologic and hematopoietic diseases; Hemophilia B - metabolism; Hemophilia B - therapy; Humans; Male; Medical sciences; Middle Aged; Platelet diseases and coagulopathies; Recombinant Fusion Proteins - pharmacokinetics; Recombinant Fusion Proteins - therapeutic use; Safety; Thrombosis and Hemostasis; Young Adult; Human; Factor IX; Hematology; Phase I trial; Hemophilia B; Hemopathy; Recombinant protein; Fusion protein; Coagulopathy; Biological activity; Genetic disease; Prolonged